In the context of neutrophil-targeted therapeutic strategies for lung cancer, several inhibitors have been developed, including the CXCR2 inhibitor SX-682, neutrophil elastase inhibitors such as Sivelestat, GW311616A, and AZD9668, as well as the NETs inhibitor DNase I, some of which are currently under clinical investigation [136, 150, 153]. Here, CXCR2 is linked to lung cancer.